Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2007
Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myelomaGeorge E Georges, Michael B Maris, David G Maloney, et al.
British Journal of Haematology|April 22, 2005
Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantationMarco Mielcarek, Lauri Burroughs, Wendy Leisenring, et al.
Blood|November 13, 2008
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomesMarco Mielcarek, Barry E Storer, Michael Boeckh, et al.
Annals of Internal Medicine|January 21, 2020
Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 CohortsGeorge B McDonald, Brenda M Sandmaier, Marco Mielcarek, et al.
Bone Marrow Transplantation|September 27, 2020
Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approachMasumi Ueda Oshima, Brenda M Sandmaier, Effie Petersdorf, et al.
Haematologica|September 29, 2018
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myelomaEnrico Maffini, Barry E Storer, Brenda M Sandmaier, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 2, 2023
Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxisEleftheria Kampouri, Danniel Zamora, Erika S Kiem, et al.
Blood|January 26, 2011
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteriaMary E D Flowers, Yoshihiro Inamoto, Paul A Carpenter, et al.
The Lancet. Haematology|June 29, 2019
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trialBrenda M Sandmaier, Brian Kornblit, Barry E Storer, et al.
Blood Advances|October 6, 2025
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamideDipenkumar Modi, Yosra M Aljawai, Todd E DeFor, et al.
Pageof 10